anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dendritic cells are a type of white blood cell used by the body to fight infection. They are instrumental in presenting antigens (such as HIV antigens) to the body's immune system. Since dendritic cells are not functioning maximally in HIV-infected patients, infusion of dendritic cells from an HIV-negative sibling may enable the affected sibling's immune system to recognize foreign particles more readily and increase immune response against the virus.

Dendritic cells from an HIV-negative sibling are obtained and treated with various viral proteins (HIV vaccines) or immunomodulators. The treated dendritic cells are infused into the HIV-infected patient monthly for 6 months. Siblings must be able to donate on multiple occasions, and patients are followed every 2-4 weeks during the study. Patients are screened over 3 months prior to study entry.
Following consent, scripted messaging will be sent three times in the first month (within the first week of signing consent at week 2 and repeated at week 3) and then once time per month for the following two months with scripted messaging reminding the participant to complete the screening activity (colonoscopy or fecal test). Digital prompts will be available in Spanish and English.
α1-antitrypsin deficiency (AATD) is a hereditary disorder with a global prevalence that differs across regions. AATD is highly prevalent in Europe and North America but rarely found in Asian countries, including Japan, possibly because of the founder effect of the pathogenic SERPINA1 variants PI*Z and PI*S. However, AATD remains underdiagnosed even in high-prevalence and low-prevalence regions, possibly because of lack of awareness. In this study, we surveyed open Japanese genetic variation databases to estimate AATD prevalence in Japan. We identified allelic frequencies (AFs) of 5 among the 14 major pathogenic SERPINA1 variants from three datasets, collectively derived from 63,119 Japanese participants. The mean AF was determined to be 8.56 × 10-4 (95% confidence interval [CI]: 6.43 × 10-4 to 1.12 × 10-3). Given that this represents the entire Japanese population, one AATD patient was speculated to be born per 1.37 × 106 births (95% CI: 7.97 × 105 to 2.42 × 106) in Japan. Our results support the prevailing notion that AATD is extremely rare in Japan.
World Health Organization (WHO) issued the latest recommendations regarding the management of drug-resistant Tuberculosis (TB) in 2022, allowing the replacement of ethambutol (6 months) with linezolid (2 months). This recommendation also introduced a new regimen, namely bedaquiline, pretomanide, linezolid, moxifloxacin (BPaLM) for fluoroquinolone-sensitive patients and bedaquiline, pretomanide, linezolid, (BPaL) for patients insensitive to fluoroquinolone (6-9 months). The latest TB regimen introduced by WHO provides a shorter-course treatment, however not much has been discussed about the impact of this new regimen on chronic kidney disease (CKD) patients, particularly on hemodialysis (HD). The condition of CKD can interfere with the pharmacokinetics of TB medication, thus could reduce effectiveness and increase toxicity. The drugs used on this new regimen are mostly safe for renal impairment patients due to the dominant metabolism in the liver. Particular precaution is given to the administration of linezolid due to increased hematology side effects and bedaquiline with the side effect of QTC interval lengthening and increased risk of arrhythmias. Although this regimen research has not been in many studies in renal failure patients, no significant side effects nor kidney damage evidence was found. This remains to be proven by more research on the patient population with renal failure.
The third group (n=50) receives standard care (see 1); personalized risk profiling (see 2); and coaching. A coach will employ behavioral change techniques (BCT) to enhance adherence using motivational interviews, feedback on behavior; and focus on the advantages of following recommendations.
Intend to train subjects in motor imagery techniques using an advanced virtual reality based platform. Hypothesize that this will enhance the cortical signals necessary for operating a non-invasive EEG-based BCI. Specifically, designed training paradigms will activate "mirror neurons" associated with performance of movement, observation of movement, and motor imagery. Mirror neuron network (MNN) activation induces cortical plasticity, and may therefore enhance cortical signals generated during BCI use. Plan to assess the effect of training paradigm on cortical signals generated during motor imagery, using EEG. Also, investigate neuropsychological factors that play a role in a subject's ability to generate vivid motor imagery.

Eight subjects with spinal cord injury (SCI) will be recruited during the sub-acute phase (3-6 months following injury). Four participants will immediately undergo motor imagery training in an immersive virtual reality environment at NASA. EEG assessments and motor function testing will be performed at intervals during the 3-4 week motor imagery training period to assess improvement in cortical signature generation and motor recovery. The other four participants will undergo the same protocol after a 6 week delay, in order to assess the effect of training timing after injury in both cortical signature generation and motor function recovery.
Techniques for use in accordance with patient care are provided. In one aspect of the invention, a technique for use in accordance with patient care comprises the following steps/operations. One or more metrics associated with one or more patients are received. One or more priorities associated with the one or more patients are determined based at least on the one or more metrics. An ordering of the one or more patients is determined, responsive to the one or more priorities. Responsive to the ordering of the one or more patients, an indicator is transmitted to at least one receiver.
Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment. The participants selected for the intervention arm will be asked not to discuss the payment with any other study participants (such as the members of any other families they may see at the NICU) or other health care staff at the NICU. Participants will also receive everything that the Comparison group receives.
TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
α-Gal syndrome (AGS) is an allergic reaction to galactose-α-1,3-galactose (α-gal) found in the salivary glands of ticks, mammalian meat excluding primates, and some antibody preparations, such as cetuximab. We report two cases of AGS diagnosed after ingestion of wild boar meat. Patient 1, a male in his 70s, developed anaphylactic shock about 3 h after eating wild boar meat. He was transported to our acute and critical care center in Nagasaki University Hospital because he had difficulty in moving. Patient 2, a female in her 60s, developed a skin rash about 2.5 h after ingesting wild boar meat. After visiting our department to investigate the cause of the disease, the sera of both patients were found to be positive for α-gal specific IgE antibody and were diagnosed with AGS caused by ingestion of wild boar meat. Reports of AGS diagnosed after ingestion of wild boar meat are rare in Japan. Compared with other prefectures, the consumption of wild boar meat in Nagasaki is relatively high in Japan. In the past 10 years, four cases of AGS were diagnosed at our department, half of which were caused by the ingestion of wild boar meat, the ratio is possibly higher than that in other prefectures in Japan.
FIELD: food industry; dietary alimentation. SUBSTANCE: food additive based on dry algae spirulina platensis additionally contains hyaluronic acid. Ratio of hyaluronic acid and algae is (1-10):(99-90). Food additive may additionally include antioxidant - vitamin C, and binding agent - starch. The proposed food additive possesses dietological, immunostimulating and healing properties due to prolonged action. EFFECT: broadened assortment of food additives. 4 cl
The test group of patients who took thyroid hormone medicine and were euthyroid \[i.e. their thyroid stimulating hormone (TSH) levels are normal\], and received injections of Thyrogen (0.9 mg daily on two consecutive days) followed by oral radioiodine.
Advanced glycation end products (AGEs) are a diverse group of compounds that are formed as a result of the non-enzymatic reaction between a reducing sugar such as glucose and the free NH2 groups of an amino acid in a protein or other biomolecule. The chemical reaction, by which these products are generated, is known as the Maillard reaction and occurs as a part of the body's normal metabolism. Such a reaction is enhanced during diabetes due to hyperglycemia, but it can also occur during the preparation, processing, and preservation of certain foods. Therefore, AGEs can also be obtained from the diet (d-AGE) and contribute to an increase of the total serum pool of these compounds. They have been implicated in a wide variety of pathological processes, mainly because of their ability to induce inflammatory responses and oxidative stress increase. They are extensively accumulated as a part of the normal aging, especially in tissues rich in long half-life proteins, which can compromise the physiology of these tissues. d-AGEs are abundant in diets rich in processed fats and sugars. This review is addressed to the current knowledge on these products and their impact on the immunomodulation of various mechanisms that may contribute to exacerbation of the diabetes pathophysiology.
In addition to the IM injection procedure, a cold needle tip will be used in the needle tip changing procedure step. For this, before the application, the 25 Gauge orange syringe tip will be placed in a cold thermos and kept at 0-2 degrees Celsius with ice batteries. The appropriate temperature range will be checked with a digital thermometer.
Intravenous administration of a liver-directed AAV vector could potentially lead to liver transaminase elevations. Transaminase elevations, particularly when observed in the first 4 months after BEQVEZ administration, is presumed to occur due to immune-mediated injury of transduced hepatocytes and may reduce the therapeutic efficacy of the AAV vector-based gene therapy. 

In clinical studies with BEQVEZ, transaminase elevations (defined as ≥1.5 x baseline) occurred in 29 of 45 and 7 of 15 patients in study 1 and study 2 respectively. Twenty-eight (62%) patients in clinical study 1 received corticosteroids for transaminase elevation and/or decline in factor IX activity. The mean time to corticosteroid initiation was 45 days. The mean duration of corticosteroid treatment was 113 days (range: 41 to 276 days). Three (20%) patients in clinical study 2 received corticosteroids for transaminase elevation and/or decline in factor IX activity with time to initiation and duration of corticosteroid use within the range seen in clinical study 1.

Monitor ALT, AST and factor IX activity levels once or twice weekly for at least 4 months and institute corticosteroid treatment in response to transaminase elevation and/or decrease in FIX activity, as required [see Dosage and Administration (2.3)]. Monitor for and manage adverse reactions secondary to corticosteroid therapy. 

For the first year following administration of BEQVEZ, advise patients to limit alcohol consumption, as alcohol may impact liver enzyme elevation and potentially reduce factor IX activity over time.
<P>PROBLEM TO BE SOLVED: To provide a method and a composition for immune response inhibition in transplantation.  <P>SOLUTION: The method is one method to induce so as to reduce an immune response in a recipient by treating the recipient with a quantity of a fibroblast or a supernatant from a fibroblast culture substance effective to reduce or inhibit host rejection of a transplant. The fibroblast or the supernatant from the fibroblast culture substance is administered before, at the same time as, or after the transplantation. The method is effective in reducing the immune response to the transplant without compromising the immune response to other external antigen. Furthermore, a method to induce reducing the immune response against a host by external tissue, that is, graft versus host disease is disclosed.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PURPOSE:To obtain an aging preventive food agent, capable of strengthening nerves and effective in enhancing dyspepsia, tonic, mind and mneme by blending flesh or an extract thereof from Terminalia chebula Retz. with powder or an extract from Terminalia belerica, Glycyrrhiza glaba var. glandulifera, etc. CONSTITUTION:An agent preventive food agent obtained by blending flesh or an extract thereof from Terminalia chebula Retz. as a principal agent with one or plural kinds of powders or extracts from Terminalia belerica, Emblica officinalis, Bacopa monniera, Centella asiatica Urban, triphala or Glycyrrhiza glaba var. glandulifera. The Terminalia chebula Retz. in an amount of 50-70% is preferably mixed with 50-70% mixture of extracts from Bacopa monniera and Glycyrrhiza glaba var. glandulifera in equal amounts. Aging inhibitory effects within a wide range, such as subvirile prevention, improvement in skin or hair or treatment of diseases in digestive systems, by administering the aforementioned food agent.
Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.
Pulmonary arterial hypertension (PAH) is characterized by progressive increase of pulmonary vascular resistance and remodeling that result in right heart failure. Recessive mutations of EIF2AK4 gene (encoding general control nonderepressible 2 kinase, GCN2) are linked to heritable pulmonary veno-occlusive disease (PVOD) in patients but rarely in patients with PAH. The role of GCN2 kinase activation in the pathogenesis of PAH remains unclear. Here, we show that GCN2 was hyperphosphorylated and activated in pulmonary vascular endothelial cells (ECs) of hypoxic mice, monocrotaline-treated rats, and patients with idiopathic PAH. Unexpectedly, loss of GCN2 kinase activity in Eif2ak4-/- mice with genetic disruption of the kinase domain induced neither PVOD nor pulmonary hypertension (PH) but inhibited hypoxia-induced PH. RNA-sequencing analysis suggested endothelin-1 (Edn1) as a downstream target of GCN2. GCN2 mediated hypoxia-induced Edn1 expression in human lung ECs via HIF-2α. Restored Edn1 expression in ECs of Eif2ak4-/- mice partially reversed the reduced phenotype of hypoxia-induced PH. Furthermore, GCN2 kinase inhibitor A-92 treatment attenuated PAH in monocrotaline-treated rats. These studies demonstrate that GCN2 kinase activation mediates pulmonary vascular remodeling and PAH at least partially through Edn1. Thus, targeting GCN2 kinase activation is a promising therapeutic strategy for treatment of PAH in patients without EIF2AK4 loss-of-function mutations.
PROBLEM TO BE SOLVED: To impart the hair with natural gloss by making fine particles adsorbed to the edge portions of the hair cuticles selectively. SOLUTION: Natural gloss is imparted to the hair by making water-insoluble polymer fine particles or inorganic fine particles >=0.2μm but <1μm (pref. 0.3-0.9μm) in average diameter absorbed to the edge portions of the hair cuticles selectively. In this case, it is preferable that 5 or more counts of the above fine particles per 1,000μm<2> unit surface area of the hair are adsorbed and >=70% of which is adsorbed to the edge portions. The adsorption is conducted by treating the hair with a hair cosmetic such as hair rinse, hair conditioner, hair treatment or hair spray. By virtue of the treatment, hair trimming disposition is improved with favorable touch feeling without the hair's getting sticky.
The invention relates to a recombination tiger gram pancreatic peptide supporter, a preparation method and application of the recombination tiger gram pancreatic peptide supporter. The recombination tiger gram pancreatic peptide supporter includes at least one copy tiger gram pancreatic peptide. Base sequence of the tiger gram pancreatic peptide is as follows: SEQ ID NO: 9. The preparation method of the recombination tiger gram pancreatic peptide supporter includes obtaining a tiger gram pancreatic peptide gene. With the tiger gram pancreatic peptide gene as a template, a copy number of tiger gram pancreatic peptide recombinant support is obtained by amplifying, enzyme digesting and connecting. The copy number of tiger gram pancreatic peptide recombinant support is enzyme digested and connected, and with the connected product as an amplifying template, a second amplifying is proceeded. A two copy numbers of the tiger gram pancreatic peptide recombinant supports are obtained by the connection of the amplifying product and the support after double enzyme digested. The step is repeated and at least three copy numbers of the tiger gram pancreatic peptide recombinant supports are sequentially obtained. The recombination tiger gram pancreatic peptide supporter has the advantages of being high in expression quantity, simple in preparation method and not obviously different from the tiger gram pancreatic peptide which is naturally obtained in biological activity.
Of the 2,978 subjects that were administered Naropin Injection in 71 controlled and uncontrolled clinical studies, 803 patients (27%) were 65 years of age or older which includes 127 patients (4%) 75 years of age and over. Naropin Injection was found to be safe and effective in the patients in these studies. Clinical data in one published article indicate that differences in various pharmacodynamic measures were observed with increasing age. In one study, the upper level of analgesia increased with age, the maximum decrease of mean arterial pressure (MAP) declined with age during the first hour after epidural administration, and the intensity of motor blockade increased with age.   
  
This drug and its metabolites are known to be excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are more likely to have decreased hepatic, renal, or cardiac function, as well as concomitant disease. Therefore, care should be taken in dose selection, starting at the low end of the dosage range, and it may be useful to monitor renal function (see  PHARMACOKINETICS,  Elimination).
PURPOSE: To estimate the effect of integrating custom-designed hand therapy video games (HTVG) with contralaterally controlled functional electrical stimulation (CCFES) therapy.
METHODS: Fifty-two stroke survivors with chronic (>6 months) upper limb hemiplegia were randomized to 12 weeks of CCFES or CCFES + HTVG. Treatment involved self-administration of technology-mediated therapy at home plus therapist-administered CCFES-assisted task practice in the lab. Pre- and post-treatment assessments were made of hand dexterity, upper limb impairment and activity limitation, and cognitive function.
RESULTS: No significant between-group differences were found on any outcome measure, and the average magnitudes of improvement within both groups were small. The incidence of technical problems with study devices at home was greater for the CCFES + HTVG group. This negatively affected adherence and may partially explain the absence of effect of HTVG. At end-of-treatment, large majorities of both treatment groups had positive perceptions of treatment efficacy and expressed enthusiasm for the treatments.
CONCLUSION: This study makes an important contribution to the research literature on the importance of environmental factors, concomitant impairments, and technology simplification when designing technology-based therapies intended to be self-administered at home. This study failed to show any added benefit of HTVG to CCFES therapy.Clinicaltrials.gov (NCT03058796).
PROBLEM TO BE SOLVED: To track the position and state information of plural medical inspection cards. SOLUTION: Actually assembled inspection kits are respectively provided with an inspection card provided with one of unique pins from the first set of related unique PINs. The first set of the unique PINs is tracked by updating a personal identification number data base in response to second digital signals. Third digital signals are provided in an inspection lab 160 from a central monitoring system. The third digital signals express the second set of the unique PINs and are provided by the central monitoring system in response to the second digital signals. Forth digital signals are received from the inspection lab 160 in the central monitoring system. The forth digital signals express the inspection card received in the inspection lab 160 from a patient.
A packaged product and methods for manufacturing the same are provided. The packaged product includes a non-aerosol container and a shaving aid composition. The container includes a pocket. The shaving aid composition is in the form of a post-foaming gel and is stored within the pocket. The container is impermeable to the shaving aid composition during a useful life of the container. The shaving aid composition has a temperature dependent characteristic that enables the shaving aid composition to be stored within the pocket at temperatures below 48°C without causing a volume of the shaving aid composition to significantly increase during the useful life of the container. The shaving aid composition can be stored within the pocket at temperatures below 48°C without causing the volume of the shaving aid composition to increase to a magnitude such that the pocket is inadvertently opened during the useful life of the container.
Carisoprodol, the active ingredient in carisoprodol tablets, has been subject to abuse, dependence, and withdrawal, misuse and criminal diversion [see Drug Abuse and Dependence (9.1, 9.2, 9.3)]. Abuse of carisoprodol poses a risk of overdosage which may lead to death, CNS and respiratory depression, hypotension, seizures, and other disorders [see Overdosage (10)].

Post-marketing experience cases of carisoprodol abuse and dependence have been reported in patients with prolonged use and a history of drug abuse. Although most of these patients took other drugs of abuse, some patients solely abused carisoprodol. Withdrawal symptoms have been reported following abrupt cessation of carisoprodol after prolonged use. Reported withdrawal symptoms included insomnia, vomiting, abdominal cramps, headache, tremors, muscle twitching, ataxia, hallucinations, and psychosis. One of carisoprodol's metabolites, meprobamate (a controlled substance), may also cause dependence [see Clinical Pharmacology (12.3)].

To reduce the risk of carisoprodol abuse, assess the risk of abuse prior to prescribing. After prescribing, limit the length of treatment to three weeks for the relief of acute musculoskeletal discomfort, keep careful prescription records, monitor for signs of abuse and overdose, and educate patients and their families about abuse and on proper storage and disposal.